Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors
Sequist, Lecia V
Yang, James Chih-Hsin
Yamamoto, Nobuyuki
O'Byrne, Kenneth
Hirsh, Vera
Mok, Tony
Geater, Sarayut Lucien
Orlov, Sergey
Tsai, Chun-Ming
Boyer, Michael
Affiliation
Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA; James Chih-Hsin Yang, National Taiwan University Hospital; Chun-Ming Tsai, Taipei Veterans General Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Kenneth O'Byrne, St James' Hospital, Dublin, Ireland; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Tony Mok, Prince of Wales Hospital, Hong Kong, China; Sarayut Lucien Geater, Songklanagarind Hospital, Songkla, Thailand; Sergey Orlov, Pavlov State Medical University, St Petersburg; Vera Gorbunova, GU Russian Oncological Research Centre, Moscow, Russia; Michael Boyer, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Jaafar Bennouna, Institut de Cancérologie de l'Ouest-site René Gauducheau, Nantes, France; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju, South Korea; Riyaz Shah, Maidstone and Tunbridge Wells National Health Service Trust, Maidstone Hospital, Maidstone; Dan Massey, Victoria Zazulina, and Mehdi Shahidi, Boehringer Ingelheim, Bracknell, United Kingdom; and Martin Schuler, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.
Issue Date
2013-09-20
Keywords
LUNG CANCER
CHEMOTHERAPY
MeSH
Adenocarcinoma
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Cisplatin
Female
Glutamates
Guanine
Humans

Metadata
Show full item record
Citation
Sequist LV et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. 2013, 31 (27):3327-34 J. Clin. Oncol.
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
URI
http://hdl.handle.net/10147/323888
DOI
10.1200/JCO.2012.44.2806
PubMed ID
23816960
Abstract
The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations. A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS).
Item Type
Article
Language
en
ISSN
1527-7755
Collections